![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
GD Olsen, KM Sommer, PL Wheeler, SR Boyea, SP Michelson and DB Cheek
Department of Pharmacology, School of Medicine, Oregon Health Sciences University, Portland.
The time course and extent of morphine-3-beta-D-glucuronide (M3G) production from morphine (MOR) and the clearance of M3G from plasma was studied in the late gestation fetal lamb. MOR was infused at a constant rate into the fetal vena cava and plasma was sampled from the fetus and ewe. Amniotic fluid was also sampled in one animal. M3G was produced in the fetal lamb and accumulated extensively in fetal plasma and amniotic fluid. Seizure activity was observed in two fetal lambs with extremely high plasma concentrations of M3G and MOR. The molar ratio of M3G to MOR in fetal plasma was dependent upon the duration of infusion, reaching a plateau of 60 at about 3 days, but appeared to be independent of the infusion rate over the range studied, 3 to 30 mg hr- 1. Maternal plasma MOR and M3G concentrations were substantially less than corresponding fetal plasma concentrations. Using the steady-state plasma concentration of M3G obtained from infusion of MOR and the clearance of M3G derived from single injection of M3G to fetal lambs, the fraction of MOR converted to M3G by the fetus was calculated to be 0.63. Although MOR is conjugated to glucuronic acid in the fetal lamb and excreted into the amniotic fluid it is not readily transferred across the epitheliochorial placenta to the ewe because of restricted permeability.
This article has been cited by other articles:
|
|
 |
|
  M. Garland, K. M. Abildskov, T.-w. Kiu, S. S. Daniel, P. Weldy, and R. I. Stark Placental Transfer and Fetal Elimination of Morphine-3-{beta}-glucuronide in the Pregnant Baboon Drug Metab. Dispos., September 1, 2008; 36(9): 1859 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Garland, K. M. Abildskov, S. Taylor, K. Benzeroual, C. S. Caspersen, S. E. Arroyo, T.-w. Kiu, B. Reznik, P. Weldy, S. S. Daniel, et al. FETAL MORPHINE METABOLISM AND CLEARANCE ARE CONSTANT DURING LATE GESTATION Drug Metab. Dispos., April 1, 2006; 34(4): 636 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Garland, K. M. Abildskov, T.-w. Kiu, S. S. Daniel, and R. I. Stark THE CONTRIBUTION OF FETAL METABOLISM TO THE DISPOSITION OF MORPHINE Drug Metab. Dispos., January 1, 2005; 33(1): 68 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kim, K. W. Riggs, and D. W. Rurak STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP Drug Metab. Dispos., February 1, 2004; 32(2): 212 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kumar, H. Wong, S. A. Yeung, K. W. Riggs, F. S. Abbott, and D. W. Rurak Disposition of Valproic Acid in Maternal, Fetal, and Newborn Sheep II: Metabolism and Renal Elimination Drug Metab. Dispos., July 1, 2000; 28(7): 857 - 864. [Abstract] [Full Text]
|
|
|
|
|
|
S. Kumar, K. W. Riggs, and D. W. Rurak Comparative Formation, Distribution, and Elimination Kinetics of Diphenylmethoxyacetic Acid (a Diphenhydramine Metabolite) in Maternal and Fetal Sheep Drug Metab. Dispos., April 1, 1999; 27(4): 463 - 470. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Kumar, G. R. Tonn, E. Kwan, C. Hall, K. W. Riggs, J. E. Axelson, and D. W. Rurak Estimation of Transplacental and Nonplacental Diphenhydramine Clearances in the Fetal Lamb: The Impact of Fetal First-Pass Hepatic Drug Uptake J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 617 - 632. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
